Dergiler / Klinik Psikofarmakoloji Bülteni / 2016 / Cilt: 26 - Sayı: 3

A Case of Chronic Schizophrenia Who were Switched from Combined Treatment to Monotherapy and Achieved a Decrease in Positive Symptoms after Lowering the

Sayfa
324–328
Yayın Tarihi
2022-10-17
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

In this article, a chronic schizophrenic case whose treatment is changed from combination of clozapine with aripiprazole to clozapine monotherapy and whose positive symptoms decreased with the decrease of clozapine doses 900 mg/day to 625 mg/day is reported.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:A case of chronic schizophrenia who were switched from combined treatment to monotherapy and achieved a decrease in positive symptoms after lowering the clozapine dose Despite the limited evidence to support the combination of antipsychotics in treatment resistant schizophrenia in the literature, this situation is common in clinical practice.
📊
Temel Bulgular & Veri:Treatment guidelines recommend monotherapy for schizophrenia primarily.
💡
Sonuç & Katkı:In this article, a chronic schizophrenic case whose treatment is changed from combination of clozapine with aripiprazole to clozapine monotherapy and whose positive symptoms decreased with the decrease of clozapine doses 900 mg/day to 625 mg/day is reported.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

A case of chronic schizophrenia who were switched from combined treatment to monotherapy and achieved a decrease in positive symptoms after lowering the clozapine dose Despite the limited evidence to support the combination of antipsychotics in treatment resistant schizophrenia in the literature, this situation is common in clinical practice. Treatment guidelines recommend monotherapy for schizophrenia primarily. In this article, a chronic schizophrenic case whose treatment is changed from combination of clozapine with aripiprazole to clozapine monotherapy and whose positive symptoms decreased with the decrease of clozapine doses 900 mg/day to 625 mg/day is reported.

🔖

Bu Makaleye Atıf Yap

HAMURCU, H. D., CAYKOYLU, A., PEKSEN, E., OZTURK, M., SEVİL, N. (2022). A Case of Chronic Schizophrenia Who were Switched from Combined Treatment to Monotherapy and Achieved a Decrease in Positive Symptoms after Lowering the. Klinik Psikofarmakoloji Bülteni, Cilt: 26 - Sayı: 3, 324–328. https://ajindex.com/articles/573903

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (7)

  1. Altinyazar V, Yuksel N. Combination treatments in schizophrenia. Klinik Psikofarmakoloji Bulteni - Bulletin of Clinical Psychopharmacology 2011;21(4):368-80. (Turkish
  2. Weinbrenner S, Assion HJ, Stargardt T, Busse R, Juckel G, Gericke CA. Drug prescription patterns in schizophrenia outpatients: analysis of data from a German health insurance fund. Pharmacopsychiatry 2009;42(2):66-71. [CrossRef] 3. Albayrak-Ozalmete O, Ceylan ME, Ozalmete O, Efe-Sevim M. Antipsychotic polypharmacy in schizophrenic inpatients. Archives of Neuropsychiatry 2010;47(1):23-8
  3. Boke O, Sarisoy G, Akbas S, Aker S, Korkmaz S, Aker AA, Bahce Z, Celik C, Sahin AR. Combined antipyschotic prescription for inpatients: A retrospective study. Klinik Psikofarmakoloji Bulteni - Bulletin of Clinical Psychopharmacology 2006;16(3):167-73. (Turkish
  4. Anil AE, Turgut IT, Rezaki M, Gogus A. A review on augmentation of clozapine treatment. Turk Psikiyatri Derg 2002;13(1):65-77. (Turkish 6. Ozalmete OA, Ozalmete EO, Ceylan ME, Sevim ME. Causes of antipsychotic polypharmacy in schizophrenia treatment. Klinik Psikofarmakoloji Bulteni - Bulletin of Clinical Psychopharmacology 2009;19(1):68-74. (Turkish
  5. Schumacher JE, Makela EH, Griffin HR. Multiple antipsychotic medication prescribing patterns. Ann Pharmacother. 2003;37(7-8):951-5. [CrossRef 8. Centorrino F, Goren JL, Hennen J, Salvatore P, Kelleher JP, Baldessarini RJ. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am J Psychiatry 2004;161(4):700-6. [CrossRef] 9. Mossaheb N, Kaufmann RM. Role of aripiprazol in treatment-resistant schizophrenia. Neuropsychiatr Dis Treat 2012;8:235-44. [CrossRef] 10. Fleischhacker WW, Heikkinen ME, Olié JP, Landsberg W, Dewaele P, McQuade RD, et al. Effects of adjunctive treatment with aripirazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 2010;13(8):1115-25. [CrossRef] 11. Devinsky O, Pacia SV. Seizures during clozapine therapy. J Clin Psychiatry 1994;55 (Suppl. B):S153-S6
  6. Pacia SV, Devinsky O. Clozapine-related seizures:experience with 5,629 patients. Neurology 1994;44(12):2247-9. [CrossRef] 13. Fujimori S, Yoneda Y. Neuropsychiatric disorders and GABA. Nihon Shinkei Seishin Yakurigaku Zasshi 2004;24(5):265-71
  7. Farber NB, Newcomer JW, Olney JW. Glycine agonists: what can they teach us about sch